Application of chronic liver failure-sequential organ failure assessment score for the predication of mortality after esophageal variceal hemorrhage post endoscopic ligation

Ming-Wun Wong¹,², Ming-Jen Chen³,⁴,⁵, Huan-Lin Chen², Yu-Chi Kuo²,⁶, I-Tsung Lin², Chia-Hsien Wu², Yuan-Kai Lee⁶, Chun-Han Cheng², Ming-Jong Bair²,⁵,⁶*

1 Department of Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan, 2 Department of Internal Medicine, Division of Gastroenterology, Taitung MacKay Memorial Hospital, Taitung, Taiwan, 3 Department of Internal Medicine, Division of Gastroenterology, MacKay Memorial Hospital, Taipei, Taiwan, 4 MacKay Medicine Nursing and Management College, Taipei, Taiwan, 5 MacKay Medical College, New Taipei, Taiwan, 6 Department of Nursing, Meiho University, Pingtung, Taiwan

* hypertr42@gmail.com

Abstract

Background

Esophageal variceal hemorrhage (EVH) is one of the high mortality complications in cirrhotic patients. Endoscopic variceal ligation (EVL) is currently the standard therapy for EVH. However, some patients have expired during hospitalization or survived shortly after management.

Aim

To evaluate hospital and 6-week mortality by receiver operating characteristic (ROC) curve of chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score compared to a model for end-stage liver disease (MELD) score and Child–Turcotte–Pugh (CTP) class.

Methods

We retrospectively collected 714 cirrhotic patients with EVH post EVL between July 2010 and June 2016 at Taitung MacKay Memorial Hospital, Taiwan. CLIF-SOFA score, MELD score, and CTP class were calculated for all patients admitted.

Results

Among the 714 patients, the overall hospital and 6-week mortality rates were 6.9% (49/715) and 13.1% (94/715) respectively. For predicting hospital death, area under receiver operating characteristic curve (AUROC) values of CLIF-SOFA score, MELD score, and CTP class were 0.964, 0.876, and 0.846. For predicting 6-week death, AUROC values of CLIF-SOFA score, MELD score, and CTP class were 0.943, 0.817, and 0.834. CLIF-SOFA score had higher AUROC value with statistical significance under pairwise comparison than did MELD score and CTP class in prediction of not only hospital but also 6-week mortality. The history
A risk factor for 6-week mortality was the diagnosis of hepatocellular carcinoma. For patients with hepatocellular carcinoma, the cut-point of CLIF-SOFA score was 5.5 for 6-week mortality and 6.5 for hospital mortality on admission. For patients without hepatocellular carcinoma, the cut-point of CLIF-SOFA score was 6.5 for both 6-week and hospital mortality.

Conclusion

CLIF-SOFA score predicted post-EVL prognosis well. For patients without hepatocellular carcinoma, CLIF-SOFA score ≥6 suggests higher 6-week mortality and CLIF-SOFA score ≥7 suggests higher hospital mortality. For patients with hepatocellular carcinoma, CLIF-SOFA score ≥7 suggests higher 6-week and hospital mortality.

Introduction

Acute esophageal variceal hemorrhage (EVH) is one of the lethal complications in patients with liver cirrhosis. Endoscopic variceal ligation (EVL) is currently the standard therapy for acute EVH[1]. Although patient survival has improved under advanced endoscopy, antibiotic prophylaxis, and vasoactive medication, the mortality rate is still up to 20% for each episode of acute variceal hemorrhage[2–5]. Some patients have died later even though the initial EVL was successful. Therefore, according to the Baveno VI consensus, 6-week mortality was suggested for primary endpoint of acute variceal hemorrhage. In addition, Child–Turcotte–Pugh (CTP) class, end-stage liver disease (MELD) score, and primary hemostasis were useful for predicting 6-week mortality[6].

The sequential organ failure assessment (SOFA) score was originally developed for predicting the outcome of patients in intensive care units (ICU)[7]. The chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score (S1 Table) was adjusted from SOFA score by assessing the six organ systems including the liver (bilirubin level), cerebral function (hepatic encephalopathy grade), coagulation (international normalized ratio (INR)), circulation (mean arterial pressure), and lung (PaO2/FiO2 or SpO2/FiO2)[8].

We aimed to evaluate predictive power of CLIF-SOFA score for 6-week and hospital mortality of patients with EVH post EVL. We also compared the result with CTP class and MELD score.

Materials and methods

Subjects

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Mackay Memorial Hospital. The patient records and information were anonymized and de-identified prior to analysis.

Seven hundred fourteen consecutive patients who underwent EVL for EVH at a single tertiary center between July 2010 and June 2016 were included in this study. All patients took terlipressin on the diagnosis of EVH[6]. The following patients were excluded: those with no evidence of liver cirrhosis, initial EVL failure, EVH managed by other techniques such as tissue adhesive therapy, balloon tamponade, or transjugular intrahepatic portacaval shunt.

Demographic data, disease history such as the cause of liver cirrhosis and hepatocellular carcinoma were obtained from the hospital medical registry. The complete blood counts, platelet count, bilirubin, INR, albumin, and creatinine levels were evaluated on the same day.
that the patients underwent endoscopic variceal ligation. CTP class was evaluated by the Pugh modification\[9\]. MELD score was calculated by United Network of Organ Sharing (UNOS) adjustments\[10\]. CLIF-SOFA score was established by EASL-CLIF consortium\[8\].

Definitions and outcomes
The EVH was defined as active bleeding on the esophageal varices or adherent clots, or white nipple signs on the esophageal varices without other sources of bleeding. The diagnosis was confirmed by endoscopy in all included patients and EVL was performed at the same time.

From the date of successful EVL, the primary endpoint of outcome was 6-week survival according to Baveno VI recommendations\[6\]. The secondary outcome was hospital survival. Follow-up for all patients was continued until December 31, 2016.

Statistical analysis
Student’s t test was used to compare differences between groups for continuous variables, and the chi-square test was employed for categorical data. Risk factors for 6-week mortality were tested by univariate Cox proportional hazards model first, and statistically significant ones were analyzed by multiple logistic forward Cox regression further. We used receiver operating characteristic (ROC) curve analysis to evaluate scoring systems\[11\]. The cut-off points was determined by best Youden index (sensitivity + specificity—1)\[12\]. Kaplan–Meier survival curves were constructed and compared using the log-rank test. All the statistical tests were two-tailed with value of \(P < 0.05\) considered significant. All statistical analyses were performed using SPSS software, version 19 (IBM SPSS Statistics, State of New York)

Results
Patient characteristics
A total of 714 consecutive patients were included in our study for analysis from July 2010 to June 2016. The overall hospital and 6-week mortality were 6.9% (49/715) and 13.1% (94/715), respectively. The mean age of the patients was 54.7 years and 560 patients were men (78.3%) and 155 were women (21.7%). There were 146 (21%) patients who had a history of hepatocellular carcinoma. According to 6-week mortality, demographical and clinical characteristics of survivors and nonsurvivors were summarized in Table 1. Alcoholic hepatitis accounted for 35% of cases, while a further 30% were hepatitis C virus infection cases as major causes of liver cirrhosis in our study. Except for history of hepatocellular carcinoma, there were no significant differences in age, gender, and cause of liver cirrhosis between survivors and nonsurvivors.

The proportion of CTP class C was 45.1% (323/715), mean MELD score was 14.3, and mean CLIP-SOFA score was 5.2 in this study.

Risk factors for 6-week and hospital mortality
S2 Table indicates 12 prognostic parameters for 6-week mortality by univariate Cox proportional hazards analysis. We then further performed Cox regression multivariate analysis.

With scoring systems excluded, history of hepatocellular carcinoma, mean arterial pressure (MAP), grade of hepatic encephalopathy, SpO2/FiO2, and serum level of bilirubin, albumin, and creatinine were independent risk factors for 6-week mortality.

With scoring systems included, only CLIF-SOFA score and hepatocellular carcinoma were independent risk factors for 6-week mortality.

S3 Table indicates 11 prognostic parameters for hospital mortality by univariate Cox proportional hazards analysis. Then we performed Cox regression multivariate analysis.
With scoring systems excluded, the result was almost the same as for 6-week mortality except for hepatocellular carcinoma. The history of hepatocellular carcinoma was not the risk factor for hospital mortality after multivariate analysis.

With scoring systems included, only CLIF-SOFA score and prothrombin time international normalized ratio (INR) were independent risk factors for hospital mortality.

Validity of the scoring systems

Table 2 summarizes the performance of different scoring systems; all three had good predictive value according to ROC. The areas under the receiver operator curve (AUROC) for predicting 6-week mortality of EVH post EVL among CLIF-SOFA score, MELD score, and CTP points were 0.943, 0.817, 0.834 respectively; the AUROC for predicting hospital mortality of EVH post EVL among CLIF-SOFA score, MELD score, and CTP points were 0.964, 0.876, 0.846 respectively. CLIF-SOFA score was the best predictive model for both hospital and 6-week mortality due to the largest AUROC with statistical significance under pairwise comparison of AUROC.

Table 1. Demographical and clinical characteristics according to 6-week mortality.

| Characteristics                   | All patients (n = 714) | Survivors (n = 621) | Nonsurvivors (n = 93) | P-value |
|-----------------------------------|-----------------------|---------------------|-----------------------|---------|
| Age (years)                       | 54.7 ± 12.7           | 54.5 ± 12.5         | 55.8 ± 14.2           | 0.380   |
| Gender (M/F)                      | 560/154               | 487/134             | 73/20                 | 0.987   |
| History of HCC (%)                | 146 (21)              | 115 (19)            | 31 (33)               | 0.001   |
| Causes of cirrhosis               |                       |                     |                       |         |
| Alcoholic                         | 256 (35)              | 230 (37)            | 26 (28)               | 0.157   |
| Hepatitis B                       | 92 (13)               | 79 (13)             | 13 (14)               | 0.406   |
| Hepatitis C                       | 214 (30)              | 175 (28)            | 39 (42)               | 0.663   |
| Alcoholic + Hepatitis B           | 48 (7)                | 45 (7)              | 3 (3)                 | 0.090   |
| Alcoholic + Hepatitis C           | 36 (5)                | 34 (6)              | 2 (2)                 | 0.097   |
| Hepatitis B + Hepatitis C         | 15 (2)                | 14 (2)              | 1 (1)                 | 0.242   |
| Alcoholic + Hepatitis B + Hepatitis C | 13 (2)         | 10 (2)              | 3 (3)                 | 0.067   |
| Other causes*                     | 40 (6)                | 34 (6)              | 6 (7)                 | 0.504   |
| MAP (mmHg)                        | 89.8 ± 20.6           | 91.1 ± 20.8         | 81.1 ± 16.5           | <0.001  |
| Hemoglobin (g/dL)                 | 9.4 ± 2.4             | 9.5 ± 2.4           | 8.6 ± 2.1             | 0.001   |
| Leucocytes (K/dL)                 | 8.0 ± 6.0             | 7.5 ± 5.8           | 10.8 ± 6.2            | <0.001  |
| Bilirubin (umol/L)                | 4.5 ± 6.0             | 3.7 ± 4.7           | 10.0 ± 9.8            | <0.001  |
| Prothrombin time INR              | 1.4 ± 0.7             | 1.4 ± 0.8           | 1.6 ± 0.5             | 0.007   |
| Albumin (g/dL)                    | 2.9 ± 0.7             | 3.0 ± 0.7           | 2.6 ± 0.5             | <0.001  |
| CTP points                        | 9.3 ± 1.7             | 4.6 ± 1.7           | 9.2 ± 2.5             | <0.001  |
| MELD score                        | 13.4 ± 6.8            | 12.9 ± 7.0          | 23.4 ± 9.7            | <0.001  |
| CLIF-SOFA score                   | 5.1 ± 2.4             | 4.6 ± 1.7           | 9.2 ± 2.5             | <0.001  |

M, male; F, female; HCC, hepatocellular carcinoma; MAP, mean arterial pressure; INR, international normalized ratio; SpO2, pulse oximetric saturation; FiO2, fractional inspired oxygen; CTP, Child–Turcotte–Pugh; MELD, model for end-stage liver disease; CLIF-SOFA, chronic liver failure-sequential organ failure assessment.

* "Other causes" includes primary biliary cirrhosis, autoimmune hepatitis, and other unknown causes.

https://doi.org/10.1371/journal.pone.0182529.t001
Table 3 revealed the cut-off point in manner of Youden index for CLIF-SOFA score, MELD score, and CTP points. The sensitivity, specificity, positive predictive values, negative predictive values, and accuracy were also shown at the best cut-off point. For CLIF-SOFA score, we identified the cut-off point of 6.5 for not only hospital but also 6-week mortality.

Since the history of hepatocellular carcinoma was one of important risk factors for 6-week mortality, we made further subgroup ROC analysis depends on with or without a history of hepatocellular carcinoma in Table 4.

In order to predict 6-week mortality, the cut-off point was 6.5 for patients with hepatocellular carcinoma. The result was similar with all patients. However, the cut-off point was changed to 5.5 for patients without hepatocellular carcinoma.

In order to predicting hospital mortality, the cut-off point was 6.5 for patients with or without hepatocellular carcinoma. The result was the same with all patients.

### Discussion

Our study demonstrated that CLIF-SOFA score was a good predictive system for not only hospital but also 6-week mortality of post successful endoscopic variceal ligation. There are several predictive models for upper gastrointestinal bleeding such as Rockall score (RS), Glasgow Blatchford Score (GBS), Baylor Bleeding score, Cedars-Sinai Medical Center predictive index, Almela score, and AIMS65 score [13–17]. Thanapirom et al. showed significantly lower AUROC for prediction of mortality and re-bleeding in variceal bleeding compared with
nonvariceal bleeding among full RS (0.57 vs. 0.80), pre-endoscopic RS (0.63 vs. 0.76), and GBS (0.63 vs. 0.66)[18]. Budimir et al. revealed AUROC for predicting variceal bleeding mortality among AIMS65, GBS and PRS were 0.74, 0.60, 0.67 respectively[19]. By contrast, Al-Freah et al. showed higher AUROC for predicting ICU hospital mortality variceal bleeding by CLIF-SOFA score (0.823), MELD score (0.839), and modified number of failed organs (0.843)[20]. In our cohort, CLIF-SOFA score predicted well for post EVL 6-week mortality as AUROC reached 0.943. According to the current literature, it seems that scoring systems consisting of liver function evaluation such as CLIF-SOFA and MELD scores predicted mortality more precisely than RS and GBS, which were used widely for general upper gastrointestinal bleeding.

Under pairwise comparison of area under the receiver operator characteristics, we indicated that the predicting power of CLIF-SOFA score was better than MELD score and CTP points for 6-week mortality of EVH post EVL in significant difference. The result could be explained by our multivariate hazard Cox analysis with parameters of scoring systems excluded. First, in addition to levels of serum bilirubin and creatinine, grade of hepatic encephalopathy, MAP, and respiration parameter SpO2/FiO2; these additional parameters were included in CLIF-SOFA score compared with MELD score. On the other hand, CLIF-SOFA score included five risk factors (grade of hepatic encephalopathy, SpO2/FiO2, MAP, serum bilirubin and creatinine) more than CTP points included two risk factors (serum albumin and grade of hepatic encephalopathy). We also considered that EVH was an acute on chronic event. Thus, CLIF-SOFA score included not only relatively chronic parameters of the liver like MELD score and CTP points but also relative acute parameters such as SpO2/FiO2 and MAP.

Table 4. CLIF-SOFA score according to history of HCC.

| Variable            | Mortality rate (%) | AUROC | 95% CI         | P-value | Mortality rate | AUROC | 95% CI         | P-value |
|---------------------|--------------------|-------|----------------|---------|----------------|-------|----------------|---------|
| All (n = 714)       | 13.1               | 0.943 | 0.917–0.968    | <0.001  | 6.9            | 0.964 | 0.949–0.979    | <0.001  |
| HCC (n = 146)       | 21.2               | 0.964 | 0.925–1.0      | <0.001  | 8.9            | 0.956 | 0.923–0.990    | <0.001  |
| Non-HCC (n = 568)   | 10.9               | 0.937 | 0.905–0.970    | <0.001  | 6.2            | 0.965 | 0.947–0.983    | <0.001  |

Cut-off points according to Youden index

| Predictive factors | Cut-off point | Sensitivity (%) | Specificity (%) | PPV   | NPV   | Accuracy |
|--------------------|--------------|----------------|----------------|-------|-------|----------|
| CLIF-SOFA          | 6.5          | 0.758          | 0.871          | 0.887 | 0.536 | 0.979    | 0.885   |
| HCC                | 6.5          | 0.834          | 0.903          | 0.930 | 0.778 | 0.973    | 0.924   |
| Non-HCC            | 5.5          | 0.742          | 0.968          | 0.775 | 0.345 | 0.995    | 0.795   |

| Predictive factors | Cut-off point | Sensitivity (%) | Specificity (%) | PPV   | NPV   | Accuracy |
|--------------------|--------------|----------------|----------------|-------|-------|----------|
| CLIF-SOFA          | 6.5          | 0.823          | 0.979          | 0.844 | 0.311 | 0.998    | 0.852   |
| HCC                | 6.5          | 0.827          | 1.0            | 0.827 | 0.361 | 1.0      | 0.842   |
| Non-HCC            | 6.5          | 0.819          | 0.971          | 0.848 | 0.296 | 0.998    | 0.856   |

CLIF-SOFA, chronic liver failure-sequential organ failure assessment; HCC, hepatocellular carcinoma

https://doi.org/10.1371/journal.pone.0182529.t004
In addition, hepatocellular carcinoma was also an independent risk factor for 6-week mortality of EVH post EVL according to multivariate hazard Cox analysis with parameters of scoring systems included. This finding was the same as previous studies, and portal thrombosis induced advanced portal hypertension was suggested as the reason[21–23]. So, the cut-off point for predicting 6-week mortality was different after subgroup analysis according to with or without a history of hepatocellular carcinoma. However, hepatocellular carcinoma was not a risk factor for hospital mortality according to hazard Cox analysis in our study. Thus, the cut-off point for predicting hospital mortality was not different after subgroup analysis.

According to our cohort, we suggested that patients (whether with or without hepatocellular carcinoma) with CLIF-SOFA score ≥7 to be more closely monitored after EVL because of higher hospital mortality. Caring for them in the ICU is one of rationales, and besides, it may reduce medical expenses to care for relatively stable patient with CLIF-SOFA score below cut-off point in the ward. On the other hand, for hospital survivors with CLIF-SOFA score ≥6 (without history of hepatocellular carcinoma) or CLIF-SOFA score ≥7 (with history of hepatocellular carcinoma), earlier treatment goal discussion such as liver transplantation or hospice care were considered due to higher 6-week mortality.

There are some strengths in our study. First, a relatively large sample size was included because our hospital is the only referring center for EVL in Taitung (a remote southeastern county in Taiwan). Second, this was the first study to evaluate EVH purely managed by EVL according to CLIF-SOFA score. Third, our overall six-week mortality was 13.1% in agreement with the published literature[24]. It also confirmed recent improvement of prognosis of EVH [4, 20, 24, 25].

However, several limitations of the current study should be mentioned. First, our study was a retrospective observational study from a single hospital. Second, we did not compare CLIF-SOFA score with other scores such as acute physiology and chronic health evaluation (APACHE) or original sequential organ failure assessment (SOFA) score. Because not all patients with EVH post-EVL were cared for in the ICU, there was insufficient data for other scores frequently used in ICU. Third, the positive and negative predictive values were based on the mortality rate in our study. These values would be changed while applied in other hospital due to different mortality.

Conclusions
CLIF-SOFA score predicts post-EVL prognosis well and may be an objective reference for physician’s decision-making. For patients without hepatocellular carcinoma, CLIF-SOFA score ≥6 suggests higher 6-week mortality and CLIF-SOFA score ≥7 suggests higher hospital mortality. For patients with hepatocellular carcinoma, CLIF-SOFA score ≥7 suggests higher 6-week and hospital mortality.

Supporting information
S1 Table. The chronic liver failure- sequential organ failure assessment (CLIF-SOFA) score.
(DOCX)
S2 Table. Cox analysis for 6-week mortality.
(DOC)
S3 Table. Cox analysis for hospital mortality.
(DOC)
S4 Table. Original individual data.
(XLSX)

**Author Contributions**

**Conceptualization:** Ming-Wun Wong, Ming-Jen Chen, Ming-Jong Bair.

**Data curation:** Yu-Chi Kuo.

**Formal analysis:** Ming-Wun Wong, Huan-Lin Chen, Yu-Chi Kuo.

**Funding acquisition:** Ming-Jong Bair.

**Investigation:** Ming-Wun Wong, Ming-Jen Chen, I-Tsung Lin, Chia-Hsien Wu, Ming-Jong Bair.

**Methodology:** Ming-Jen Chen, Yuan-Kai Lee, Chun-Han Cheng.

**Project administration:** Ming-Wun Wong, Ming-Jen Chen, Ming-Jong Bair.

**Resources:** Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Chun-Han Cheng, Ming-Jong Bair.

**Software:** Ming-Wun Wong, Yu-Chi Kuo.

**Supervision:** Ming-Wun Wong, Ming-Jen Chen, Ming-Jong Bair.

**Validation:** Ming-Jong Bair.

**Visualization:** Ming-Wun Wong, Ming-Jong Bair.

**Writing – original draft:** Ming-Wun Wong, Ming-Jen Chen.

**Writing – review & editing:** Ming-Wun Wong, Ming-Jen Chen, Huan-Lin Chen, Ming-Jong Bair.

**References**

1. Dai C, Liu WX, Jiang M, Sun MJ. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World journal of gastroenterology. 2015; 21(8):2534–41. https://doi.org/10.3748/wjg.v21.i8.2534 PMID: 25741164

2. Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008; 57(6): 814–20. https://doi.org/10.1136/gut.2007.137489 PMID: 18250126

3. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004; 40(3): 652–9. https://doi.org/10.1002/hep.20339 PMID: 15349904

4. McCormick PA O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut. 2001; 49(5): 682–5. https://doi.org/10.1136/gut.49.5.682 PMID: 11600472

5. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol. 2000; 95(12): 3566–73. https://doi.org/10.1111/j.1572-0241.2000.03376.x PMID: 11151893

6. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of hepatology. 2015; 63(3): 743–52. https://doi.org/10.1016/j.jhep.2015.05.022 PMID: 26047908

7. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine. 1996; 22(7): 707–10. PMID: 864239

8. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7): 1426–37, 37 e1-9. https://doi.org/10.1053/j.gastro.2013.02.042 PMID: 23474284
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8): 646–9. PMID: 4541913
10. Kamath PS, Wiesner RH, Malinchoc M, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2): 464–70. https://doi.org/10.1053/jhep.2001.22172 PMID: 11172350
11. Zou KH O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007; 115(5): 654–7. https://doi.org/10.1161/CIRCULATIONAHA.105.594929 PMID: 17283280
12. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3(1): 32–5. PMID: 15405679
13. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996; 38(3): 316–21. PMID: 8675081
14. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000; 356(9238): 1318–21. https://doi.org/10.1016/S0140-6736(00)02816-6 PMID: 11073021
15. Kuipers EJ. Endoscopy: Risk assessment in upper gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol. 2010; 7(9): 480–2. https://doi.org/10.1038/nrgastro.2010.119 PMID: 20811363
16. Almela P, Benages A, Peiro S, Anon R, Perez MM, Pena A, et al. A risk score system for identification of patients with upper-GI bleeding suitable for outpatient management. Gastrointest Endosc. 2004; 59(7): 772–81. PMID: 15173788
17. Hyett BH, Abougergi MS, Charpentier JP, Kumar NL, Brozovic S, Cigagett BL, et al. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointest Endosc. 2013; 77(4): 551–7. https://doi.org/10.1016/j.gie.2012.11.022 PMID: 23357496
18. Thanapriom K, Rittitid W, Rerknimitr R, Thungsuk R, Noophun P, Wongjitrat C, et al. Comparative analysis of three risk scoring systems in non-variceal and variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol. 2016; 31(4): 761–7. https://doi.org/10.1111/jgh.13222 PMID: 26514879
19. Budimir I, Gradiser M, Nikolic M, Barsic N, Ljubicic N, Kralj D, et al. Glasgow Blatchford, pre-endoscopic Rockall and AIMS65 scores show no difference in predicting rebleeding rate and mortality in variceal bleeding. Scand J Gastroenterol. 2016; 51(11): 1375–9. https://doi.org/10.1080/00365521.2016.1200138 PMID: 27356670
20. Al-Freah MA, Gera A, Martini S, McPhail MJ, Devlin J, Harrison PM, et al. Comparison of scoring systems and outcome of patients admitted to a liver intensive care unit of a tertiary referral centre with severe variceal bleeding. Aliment Pharmacol Ther. 2014; 39(11): 1286–300. https://doi.org/10.1111/apt.12744 PMID: 24738606
21. Amitrano L, Guardascione MA, Bennato R, Manguso F, Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. Journal of hepatology. 2005; 42(6): 820–5. https://doi.org/10.1016/j.jhep.2005.01.021 PMID: 15885352
22. Letier MH, Krige JE, Lemmer ER, Terblanche J. Injection sclerotherapy for variceal bleeding in patients with irreplaceable hepatocellular carcinoma. Hepatogastroenterology. 2000; 47(36): 1680–4. PMID: 11149031
23. Cho H, Nagata N, Shimbo T, Sakurai T, Sekine K, Okubo H, et al. Recurrence and prognosis of patients emergently hospitalized for acute esophageal variceal bleeding: A long-term cohort study. Hepatol Res. 2016; 46(13): 1338–46. https://doi.org/10.1111/hepr.12692 PMID: 26946225
24. de Souza AR, Lura La Mura V, Berzigotti A, Garcia-Pagan JC, Abraldes JG, Bosch J. Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis. Hepatology. 2015; 62(6): 1840–6. https://doi.org/10.1002/hep.28151 PMID: 26340692
25. Stokkeland K, Brandt L, Ekborn A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969–2002. Hepatology. 2006; 43(3): 500–5. https://doi.org/10.1002/hep.21089 PMID: 16496319